D3-GHR Polymorphism and Turner Syndrome

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

The protein polymorphism of the growth hormone receptor characterized by the genomic deletion of exon 3 has been linked to the magnitude of the first-year-growth response to growth hormone (GH) in girls with Turner syndrome.

Objective: to study the long-term effect of GH therapy in Turner syndrome in correlation to this GHR polymorphism in a mainly retrospective design (chart-review).

Details

• Lead Sponsor: University Hospital Tuebingen
• Treatments: Hormones

Criteria

Inclusion Criteria:

• Turner syndrome defined by a structural aberration or lack of the X chromosome.

• Growth velocity less than 2 cm/year at the time of final analysis (= final height).

Exclusion Criteria:

• Age <3.5 or >14 years at start of GH therapy,

• GH peak serum levels < 8 ng/ml in two independent tests,

• Thelarche at start or during the first year of treatment,

• Oxandrolone therapy for any time and a duration of GH therapy less than 2 years.